MX2018009125A - Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular. - Google Patents

Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular.

Info

Publication number
MX2018009125A
MX2018009125A MX2018009125A MX2018009125A MX2018009125A MX 2018009125 A MX2018009125 A MX 2018009125A MX 2018009125 A MX2018009125 A MX 2018009125A MX 2018009125 A MX2018009125 A MX 2018009125A MX 2018009125 A MX2018009125 A MX 2018009125A
Authority
MX
Mexico
Prior art keywords
ocular surface
treating ocular
eye
prostacyclin
antagonists
Prior art date
Application number
MX2018009125A
Other languages
English (en)
Inventor
Wang Weizhen
Frederick Woodward David
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of MX2018009125A publication Critical patent/MX2018009125A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere en general a las composiciones y métodos para tratar eventos nociceptivos o aliviar los síntomas asociados con esos eventos. El método incluye administrar un antagonista de IP a al menos un ojo del paciente. Los eventos nociceptivos pueden estar asociados con la superficie ocular y pueden ser causados por ojos secos, lesión de la superficie ocular, ulceración, infección, alergia, contaminación o cirugía ocular.
MX2018009125A 2016-01-25 2017-01-24 Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular. MX2018009125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/006,085 US9827225B2 (en) 2016-01-25 2016-01-25 Use of prostacyclin antagonists for treating ocular surface nociception
PCT/US2017/014677 WO2017132115A1 (en) 2016-01-25 2017-01-24 Use of prostacyclin antagonists for treating ocular surface nociception

Publications (1)

Publication Number Publication Date
MX2018009125A true MX2018009125A (es) 2018-11-29

Family

ID=59360031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009125A MX2018009125A (es) 2016-01-25 2017-01-24 Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular.

Country Status (10)

Country Link
US (4) US9827225B2 (es)
EP (1) EP3407975B1 (es)
JP (1) JP6752439B2 (es)
KR (1) KR20180104108A (es)
CN (1) CN108883307B (es)
AU (1) AU2017212343B2 (es)
CA (1) CA3012197A1 (es)
ES (1) ES2894916T3 (es)
MX (1) MX2018009125A (es)
WO (1) WO2017132115A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
CA3206609A1 (en) * 2021-02-05 2022-08-11 Weizhen Wang Compositions and methods for periorbital administration of ep2 receptor agonists
KR20230158076A (ko) * 2021-03-18 2023-11-17 제니비젼 인크. 눈 질환을 치료하기 위한 방법 및 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2105333T3 (es) * 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions
US6184242B1 (en) * 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CA2427900A1 (en) * 2000-11-14 2002-05-23 F. Hoffmann-La Roche Ag Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
CN100372532C (zh) * 2003-05-01 2008-03-05 弗·哈夫曼-拉罗切有限公司 用作ip拮抗剂的咪唑啉-2-基氨基苯基酰胺
US9610990B2 (en) * 2009-05-08 2017-04-04 Titan Trailers Inc. Apparatus and method for warming the floor of a trailer
EP2794574B1 (en) 2011-12-21 2017-11-08 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception

Also Published As

Publication number Publication date
EP3407975A4 (en) 2020-02-12
WO2017132115A1 (en) 2017-08-03
ES2894916T3 (es) 2022-02-16
AU2017212343B2 (en) 2022-01-20
US20170209418A1 (en) 2017-07-27
CN108883307A (zh) 2018-11-23
AU2017212343A1 (en) 2018-08-09
US20210212993A1 (en) 2021-07-15
EP3407975B1 (en) 2021-08-18
US20200345697A1 (en) 2020-11-05
CA3012197A1 (en) 2017-08-03
US11857537B2 (en) 2024-01-02
JP6752439B2 (ja) 2020-09-09
US9827225B2 (en) 2017-11-28
JP2019502719A (ja) 2019-01-31
CN108883307B (zh) 2021-03-26
US20180008578A1 (en) 2018-01-11
EP3407975A1 (en) 2018-12-05
KR20180104108A (ko) 2018-09-19

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
CO7250451A2 (es) Formulación oftálmica y método para mitigar la presbicia
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MY187552A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
MX2018009125A (es) Uso de antagonistas de prostaciclina para el tratamiento de la nocicepcion de la superficie ocular.
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CA3073829A1 (en) Methods and compositions for detecting and treating endometriosis
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
WO2015114163A3 (de) Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors